Clinical Trial Update: Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout [Phase 3]

View source ↗

Summary

An open-label extension of a Phase 3 study of pegloticase (PEG-uricase) for symptomatic gout has completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• KRYSTEXXA (pegloticase)

Snippet

Sponsor: Savient Pharmaceuticals | Conditions: Gout | Phase 3 | Status: COMPLETED | Results posted: 2011-12-02